The third proposed drug ‘dovitinib’ acts as an antagonist of some RCC-causing genes (VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR2, and FGFR3) according to an experimental study report155. The gene discussed is FGFR2; the disease is renal cell carcinoma.